Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALK inhibitors
Pharma
Roche's Alecensa snags FDA postsurgery nod in lung cancer
In addition to the adjuvant approval, Roche is also testing Alecensa in patients with unresectable tumors and as a neoadjuvant therapy.
Angus Liu
Apr 19, 2024 11:03am
ESMO: Roche's Alecensa cuts postsurgery lung cancer recurrence
Oct 21, 2023 10:30am
Alecensa gives Roche another win in early-stage lung cancer
Sep 1, 2023 10:36am
Pfizer gains its fourth FDA approval for an ALK-positive tumors
Jul 15, 2022 10:49am
Pfizer's Xalkori follow-on, Lorbrena, snags front-line NSCLC nod
Mar 4, 2021 10:54am
Pfizer's Lorbrena blows by Xalkori in bid for front-line use
Sep 19, 2020 1:00pm
